Showing results (321-330 of 396) with videos related to
Sort By:
Pageof 40
The New England Journal of Medicine|June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutationPaul B Chapman, Axel Hauschild, Caroline Robert, et al.The New England Journal of Medicine|February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibJeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1BAmy S Clark, Fangxin Hong, Richard S Finn, et al.JCO Precision Oncology|February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1HMohamed A Gouda, Zihan Wei, Jordi Rodon, et al.The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.Nature Immunology|July 31, 2019
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistanceVivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.Cancer Discovery|May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid TumorsAmita Patnaik, Lee S Rosen, Sara M Tolaney, et al.Nature Immunology|September 26, 2019
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistanceVivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.Cancer Discovery|October 10, 2013
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2Michael P O'Connell, Katie Marchbank, Marie R Webster, et al.Pageof 40